Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Neoplasms × icotinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 18 Lung Neoplasms 7 NSCLC 3 Brain Neoplasms 3 Squamous Cell Carcinoma of Lung 1 Non-squamous Non-small Cell Lung Cancer 1 Non-small Cell Lung Cancer Metastatic 1 Non-Small-Cell Lung 1 Neuroma, Acoustic 1 Neurofibromatosis 2 1 Neoplasms, Second Primary 1 Neoplasms 1 Neoplasm Metastasis 1 Nasopharyngeal Carcinoma 1 Esophageal Neoplasms 1 Drug-Related Side Effects and Adverse Reactions 1 Bronchial Neoplasms 1 Breast Neoplasms 1 Adenocarcinoma of Lung 1

Interventions

Surveys and Questionnaires 98 Exercise 88 Blood Specimen Collection 86 Radiotherapy 60 Gemcitabine 53 Bevacizumab 52 Cisplatin 50 Standard of Care 49 Capecitabine 47 Dexamethasone 44 Cyclophosphamide 44 Carboplatin 44 Docetaxel 41 Paclitaxel 40 Interviews as Topic 40 pembrolizumab 39 Oxaliplatin 38 Methods 35 Irinotecan 35 Fluorouracil 35 Magnetic Resonance Spectroscopy 33 Therapeutics 29 Radiosurgery 28 Nivolumab 27 Drug Therapy 26 Educational Status 25 Leucovorin 22 Everolimus 21 Control Groups 21 Cognitive Behavioral Therapy 20

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03736837 2021-03-15

ALTER-L004

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡